机译:BRAF和MEK抑制剂重新接受转移性黑素瘤患者的有效治疗方法
Maria Sklodowska Curie Natl Res Inst Oncol Cracow Branch Clin Oncol Clin Krakow Poland;
Polish Acad Sci Mossakowski Med Res Ctr Maria Sklodowska Curie Natl Res Inst Oncol Dept Soft;
Polish Acad Sci Mossakowski Med Res Ctr Maria Sklodowska Curie Natl Res Inst Oncol Dept Soft;
Univ Med Sci Heliodor Swiecicki Clin Hosp Dept Med &
Expt Oncol Poznan Poland;
Holy Cross Canc Ctr Clin Oncol Clin Kielce Poland;
Maria Sklodowska Curie Natl Res Inst Oncol Gliwice Branch Dept Radiotherapy &
Chemotherapy;
Ctr Oncol Lublin Reg St Jana Dukli Clin Oncol Dept Lublin Poland;
Nicolaus Copernicus Univ Torun Ludwik Rydygier Coll Med Bydgoszcz Dept Oncol &
Brachytherapy;
Beskid Oncol Ctr Clin Oncol Dept Bielsko Biala Poland;
Polish Acad Sci Mossakowski Med Res Ctr Maria Sklodowska Curie Natl Res Inst Oncol Dept Soft;
Maria Sklodowska Curie Natl Res Inst Oncol Cracow Branch Clin Oncol Clin Krakow Poland;
Maria Sklodowska Curie Natl Res Inst Oncol Gliwice Branch Dept Radiotherapy &
Chemotherapy;
Univ Med Sci Heliodor Swiecicki Clin Hosp Dept Med &
Expt Oncol Poznan Poland;
Polish Acad Sci Mossakowski Med Res Ctr Maria Sklodowska Curie Natl Res Inst Oncol Dept Soft;
melanoma; metastatic melanoma; rechallenge; targeted therapy;
机译:对Ipilimumab / Nivolumab重新检查和BRAF抑制剂/ MEK抑制剂在患者中重新检查,所述患者预先用BRAF靶向治疗和免疫治疗治疗
机译:基于循环肿瘤DNA分析的BRAF和MEK抑制剂联合有效治疗转移性黑色素瘤患者:病例报告
机译:新一代测序显示,MEK抑制剂治疗对患有BRAF和NRAS突变的Vater壶腹转移癌患者有效
机译:黑色素瘤中BRAF抑制剂抗性的基因表达模型预测新型组合疗法的药物重新培养
机译:优化NRAS突变体黑素瘤耐久性和组合策略中的MEK抑制剂
机译:对Ipilimumab / Nivolumab重新检查和BRAF抑制剂/ MEK抑制剂在患者中重新检查所述患者预先用BRAF靶向治疗和免疫治疗治疗
机译:MEK1 / MEK2抑制剂曲美替尼在先前接受或不接受BRAF抑制剂治疗的转移性BRAF突变型皮肤黑色素瘤患者中的II期研究
机译:应用连接图谱数据库分析与黑色素瘤基因特征检测新药物治疗黑色素瘤患者。